The agreement is worth US$32 million in the short term, the announcement said, with Insilico using its AI drug-discovery tools to search for cancer treatments and the more established Servier taking up promising candidates for clinical trials and commercialization. (The Logic)

Talking point: Insilico has offices on several continents, including one in Montreal where the head of its AI development team works; founder and CEO Alex Zhavoronkov is also Canadian. The company, which does not yet have a drug on the market, went public on Hong Kong’s stock exchange at the end of 2025, raising HK$2.277 billion (the equivalent of about C$402 million at current rates), more than the HK$2.03 billion it intended. Insilico said the 10 per cent of the offering reserved for Hong Kong investors was oversubscribed by more than 1,427 times, though its share price has risen just under seven per cent since the listing. Servier produces both generic and brand-name drugs and has operated in Canada since 1978.